Ari Hakimi

Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP)

New York, NY 10065

United States

SCHOLARLY PAPERS

2

DOWNLOADS

19

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

IRF8 Governs Tumor-Associated Macrophage Control of T Cell Exhaustion

Number of pages: 69 Posted: 27 Mar 2020
Memorial Sloan Kettering Cancer Center - Immunology Program, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunology Program, Memorial Sloan Kettering Cancer Center - Immunology Program, Memorial Sloan Kettering Cancer Center - Immunology Program, Memorial Sloan Kettering Cancer Center - Immunology Program, Washington University in St. Louis - Department of Pathology and Immunology, Memorial Sloan Kettering Cancer Center - Immunology Program, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Urology Service, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center - Urology Service, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Washington University in St. Louis - Department of Pathology and Immunology, Harvard Medical School - Center for Immunology and Inflammatory Diseases, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP) and Memorial Sloan Kettering Cancer Center - Immunology Program
Downloads 12 (620,978)

Abstract:

Loading...

Tumor-associated macrophage, antigen presentation, cytotoxic T lymphocyte, cancer

2.

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint Inhibitors

Number of pages: 37 Posted: 23 Jul 2020
Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Information Systems, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics and Memorial Sloan Kettering Cancer Center - Department of Surgery
Downloads 7 (656,336)

Abstract:

Loading...

Immune Checkpoint Inhibitors; Immunotherapy; Neutrophil-to-Lymphocyte Ratio; Biomarkers